[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540886":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":25,"responsibleParty":54,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},{"fullName":5,"class":6},"Eisai Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants",null,"Participants prescribed lecanemab by a physician in routine clinical practice (post-marketing surveillance) will be observed prospectively for up to a maximum of 156 weeks or to the time of discontinuation, whichever occurs first.",[13],"Other: No Intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No Intervention","This is a non-interventional study.",[9],[21],{"name":22,"role":23,"phone":10,"phoneExt":10,"email":24},"Eisai Inquiry Service.","CONTACT","eisai-chiken_hotline@hhc.eisai.co.jp",[26,38,46],{"facility":27,"status":28,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"Eisai trial site 2","RECRUITING","Hiroshima","Japan","JP",{"type":33,"coordinates":34},"Point",[35,36],132.45,34.4,{"lat":36,"lon":35},{"facility":39,"status":28,"city":40,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":41,"geoPoint":45,"contacts":10},"Eisai trial site 3","Kyoto",{"type":33,"coordinates":42},[43,44],135.75385,35.02107,{"lat":44,"lon":43},{"facility":47,"status":28,"city":48,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":49,"geoPoint":53,"contacts":10},"Eisai trial site 1","Tokyo",{"type":33,"coordinates":50},[51,52],139.69171,35.6895,{"lat":52,"lon":51},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100540886","a-post-marketing-study-in-participants-with-early-alzheimers-disease-treated-with-lecanemab-100540886",false,"NCT06322667","A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab","A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab","Inclusion Criteria:\n\n* All participants who are treated with lecanemab in routine clinical practice\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":66,"type":67},5000,"ESTIMATED","OBSERVATIONAL","The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.",[71],"Alzheimer's Disease",[73,74,75],"Early Alzheimer's Disease","Lecanemab","ARIA","2026-01-22",{"date":78,"type":79},"2026-01-23","ACTUAL",{"date":81,"type":79},"2024-02-14",{"date":83,"type":67},"2027-12-31",{"name":85,"class":6},"Eisai Co., Ltd.",3]